First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment — — Savolitinib ...

ImmunityBio (IBRX) is back in focus after the company reported positive ANKTIVA data in non small cell lung cancer, with QUILT-2.023 and QUILT-3.055 suggesting meaningful immune restoration and ...

The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...

The company said that responding patients lived longer overall, with a median survival of 16.2 months. ・The data come from ...

TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either Dato-DXd (6.0 mg/kg intravenously every 3 weeks) or docetaxel (75 mg/m² ...

Oncoscope launches the first Real-time, AI-supported Living Systematic Literature Review designed for enterprise-wide ...

Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.

A new report from the American Cancer Association predicts lung cancer will cause more deaths than any other in 2026.

Perioperative nivolumab plus chemotherapy improves event free survival and pathological response in stage III non-small-cell ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...